News | March 31, 2021
Investment opportunities in India’s healthcare sector: NITI Aayog
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The vaccine was 85 percent effective in preventing severe disease across all regions.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
The partnership is a significant step in delivering advanced cancer therapies to patients.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
